Literature DB >> 2496062

Toxicological aspects of a novel 9-aminoanthracycline, SM-5887.

S Morisada1, Y Yanagi, Y Kashiwazaki, M Fukui.   

Abstract

The toxicological characteristics of SM-5887 were evaluated in mice after a bolus intravenous injection, and compared with those of adriamycin (ADR). The acute toxic signs observed after SM-5887 administration were body weight decrease, ataxia, hair loss, and myelosuppression. They were qualitatively comparable to those induced by ADR. The 50% lethal dose values determined by 14-day observation after drug administration were in the range of 32 to 50 mg/kg for SM-5887 and 16 to more than 20 mg/kg for ADR in four strains of mice. The maximum tolerated doses (MTD) were estimated to be 25 mg/kg for SM-5887 and 12.5 mg/kg for ADR (no death or body weight loss of more than 3 g occurred). When 14-day survivors were further observed until 90 days after drug administration, ADR frequently and dose-independently showed delayed-type lethal toxicity at doses of more than 10 mg/kg, whereas SM-5887 did not. The myelosuppression of SM-5887 was more severe even at a half of the MTD than that of ADR at the MTD, but its recovery was more rapid than that after ADR. In addition, when the drugs were injected into the subplantar region of mouse hind paws, ADR induced a severe inflammatory reaction, whereas SM-5887 yielded only a slight one. The data suggest that toxic effects of SM-5887 are more reversible and more controllable than those of ADR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496062      PMCID: PMC5917682          DOI: 10.1111/j.1349-7006.1989.tb02248.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  5 in total

1.  Skin ulcers due to adriamycin.

Authors:  R Rudolph; R S Stein; R A Pattillo
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

2.  Long persistence of doxorubicin in human skin after extravasation.

Authors:  P Sonneveld; H A Wassenaar; K Nooter
Journal:  Cancer Treat Rep       Date:  1984-06

3.  Characteristics and effect of antiinflammatory drugs on adriamycin-induced inflammation in the mouse paw.

Authors:  D M Siegel; S N Giri; R M Scheinholtz; L W Schwartz
Journal:  Inflammation       Date:  1980-06       Impact factor: 4.092

4.  Clinical course and management of accidental adriamycin extravasation.

Authors:  J J Reilly; J P Neifeld; S A Rosenberg
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

5.  Absence of delayed lethality in mice treated with aclacinomycin A.

Authors:  T H Corbett; D P Griswold; B J Roberts; F M Schabel
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

  5 in total
  10 in total

1.  Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.

Authors:  Takahiko Sugiura; Yutaka Ariyoshi; Shunichi Negoro; Shinichiro Nakamura; Harumichi Ikegami; Minoru Takada; Takashi Yana; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

2.  Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.

Authors:  Toshiyuki Sawa; Takashi Yana; Minoru Takada; Takahiko Sugiura; Shinzoh Kudoh; Tadashi Kamei; Takeshi Isobe; Hidehiko Yamamoto; Soichiro Yokota; Nobuyuki Katakami; Yuji Tohda; Akira Kawakami; Yoichi Nakanishi; Yutaka Ariyoshi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

3.  Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.

Authors:  T Takagi; Y Yazawa; K Suzuki; Y Yamauchi; Y Kano
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

Authors:  T Suzuki; S Minamide; T Iwasaki; H Yamamoto; H Kanda
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Koji Takeda; Nobuhide Takifuji; Shunichi Negoro; Kiyoyuki Furuse; Shinichiro Nakamura; Yoshiki Takada; Takanobu Hoso; Shinichi Hayasaka; Takashi Nakano; Jun Araki; Hiroshi Senba; Fumiyuki Iwami; Yasufumi Yamaji; Masahiro Fukuoka; Harumichi Ikegami
Journal:  Invest New Drugs       Date:  2007-03-10       Impact factor: 3.850

6.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.

Authors:  T Noda; T Watanabe; A Kohda; S Hosokawa; T Suzuki
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

7.  Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Takashi Yana; Shunichi Negoro; Minoru Takada; Soichiro Yokota; Yoshiki Takada; Takahiko Sugiura; Hidehiko Yamamoto; Toshiyuki Sawa; Masaaki Kawahara; Nobuyuki Katakami; Yutaka Ariyoshi; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2006-10-13       Impact factor: 3.651

8.  Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.

Authors:  Daiki Ogawara; Minoru Fukuda; Yoichi Nakamura; Shigeru Kohno
Journal:  Cancer Manag Res       Date:  2010-08-11       Impact factor: 3.989

9.  Novel Anthracycline Utorubicin for Cancer Therapy.

Authors:  Lorena Simón-Gracia; Valeria Sidorenko; Ain Uustare; Ivan Ogibalov; Andrus Tasa; Olga Tshubrik; Tambet Teesalu
Journal:  Angew Chem Int Ed Engl       Date:  2021-06-01       Impact factor: 16.823

10.  Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.

Authors:  Yosuke Dotsu; Hiroyuki Yamaguchi; Minoru Fukuda; Takayuki Suyama; Noritaka Honda; Yasuhiro Umeyama; Hirokazu Taniguchi; Hiroshi Gyotoku; Shinnosuke Takemoto; Ryuta Tagawa; Ryosuke Ogata; Hiromi Tomono; Midori Shimada; Hiroaki Senju; Katsumi Nakatomi; Seiji Nagashima; Hiroshi Soda; Hiroaki Ikeda; Kazuto Ashizawa; Hiroshi Mukae
Journal:  J Clin Med       Date:  2021-09-17       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.